Article Trunk



Posts Tagged ‘Life Sciences’

Zymergen raised $300 million because synthetic biology is so hot right now

Zymergen, one of the companies that’s developing biomanufacturing technologies which could reshape any number of industries, said it has raised $300 million in financing yesterday. It’s part of a wave of biotech companies that TechCrunch covered in depth last month. Synthetic biology startups are giving investors an appetite The investment total, announced yesterday, includes Series ...

Synthetic biology startups are giving investors an appetite

There’s a growing wave of commercial activity from companies that are creating products using new biological engineering technologies. Perhaps the most public (and tastiest) example of the promise biomanufacturing holds is Impossible Foods . The meat replacement company whose ground plants (and bioengineered additives) taste like ground beef just raised another $200 million earlier this ...

Mission Bio raises $70 million to help scale its tech for improving the development of targeted cancer therapies

California-based startup Mission Bio has raised a new $70 million Series C funding round, led by Novo Growth and including participation from Soleus Capital and existing investors Mayfield, Cota and Agilent. Mission Bio will use the funding to scale its Tapestri Platform, which uses the company’s work in single-cell multi-omics technology to help optimize clinical ...

Mammoth Biosciences lands exclusive license to new CRISPR proteins that could boost gene editing precision

CRISPR pioneer Mammoth Biosciences has secured an exclusive license to a new family of CRISPR proteins. Obtained from UC Berkeley, the license covers R&D and commercialization across all potential fields. This is a significant addition to Mammoth’s intellectual property holdings, as this new family of CRISPR proteins, known as the Casɸ family, is roughly half ...

Atomwise’s machine learning-based drug discovery service raises $123 million

With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions. Now the company has raised $123 million in ...

You’ve heard of CRISPR, now meet its newer, savvier cousin CRISPR Prime

CRISPR, the revolutionary ability to snip out and alter genes with scissor-like precision, has exploded in popularity over the last few years and is generally seen as the standalone wizard of modern gene-editing. However, it’s not a perfect system, sometimes cutting at the wrong place, not working as intended and leaving scientists scratching their heads. ...

UK biotech startup Mogrify injects $16M to get novel cell therapies to market soon

Cambridge, UK-based biotech startup Mogrify, which is working on systematizing the development of novel cell therapies in areas such as regenerative medicine, has closed an initial $16 million Series A. The raise follows a $4M seed in February — taking its total raised to date to $20M. Put simply, Mogrify’s approach entails analysis of vast ...

DNA Script picks up $38.5 million to make DNA production faster and simpler

DNA Script has raised $38.5 million in new financing to commercialize a process that it claims is the first big leap forward in manufacturing genetic material. The revolution in synthetic biology that’s reshaping industries from medicine to agriculture rests on three, equally important pillars. They include: analytics — the ability to map the genome and ...

XGenomes is bringing DNA sequencing to the masses

As healthcare moves toward genetically tailored treatments, one of the biggest hurdles to truly personalized medicine is the lack of fast, low-cost genetic testing. And few people are more familiar with the problems of today’s genetic diagnostics tools than Kalim Mir, the 52-year-old founder of XGenomes, who has spent his entire professional career studying the ...

Mammoth Biosciences adds the final piece of the CRISPR diagnostics puzzle to its toolkit

With the announcement today that Mammoth Biosciences has received the exclusive license from the University of California, Berkeley to the new CRISPR protein Cas14, the company now has the last piece of its diagnostics toolkit in place. Cas14 is a newly discovered protein from the lab of Jennifer Doudna, a pioneer in gene-editing research and ...